ZA200901011B - Improved NanobodiesTM against tumor necrosis factor-alpha - Google Patents

Improved NanobodiesTM against tumor necrosis factor-alpha

Info

Publication number: ZA200901011B
Authority: ZA; South Africa
Prior art keywords: nanobodies; polypeptides; alpha; necrosis factor; tumor necrosis
Prior art date: 2005-05-18

Application number

ZA200901011A

Other languages

English (en)

Inventor

Els Beirnaert

Original Assignee

Ablynx Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-18

Filing date

2009-02-12

Publication date

2010-04-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200901011(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-02-12 Application filed by Ablynx Nv filed Critical Ablynx Nv

2010-04-28 Publication of ZA200901011B publication Critical patent/ZA200901011B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Psychiatry (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
General Engineering & Computer Science (AREA)
Pulmonology (AREA)
Hematology (AREA)
Addiction (AREA)
Microbiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)

ZA200901011A 2005-05-18 2009-02-12 Improved NanobodiesTM against tumor necrosis factor-alpha ZA200901011B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US68233205P	2005-05-18	2005-05-18

Publications (1)

Publication Number	Publication Date
ZA200901011B true ZA200901011B (en)	2010-04-28

Family

ID=36954329

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
ZA200709867A ZA200709867B (en)	2005-05-18	2007-11-15	Improved nanobodiesTM against tumor necrosis factor-alpha
ZA200901011A ZA200901011B (en)	2005-05-18	2009-02-12	Improved NanobodiesTM against tumor necrosis factor-alpha
ZA2011/00385A ZA201100385B (en)	2005-05-18	2011-01-14	Improved nanobodies tm againt tumor necrosis factor-alpha

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
ZA200709867A ZA200709867B (en)	2005-05-18	2007-11-15	Improved nanobodiesTM against tumor necrosis factor-alpha

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ZA2011/00385A ZA201100385B (en)	2005-05-18	2011-01-14	Improved nanobodies tm againt tumor necrosis factor-alpha

Country Status (29)

Country	Link
US (6)	US8188223B2 (xx)
EP (7)	EP3613767A1 (xx)
JP (4)	JP5047950B2 (xx)
KR (1)	KR101308771B1 (xx)
CN (2)	CN101248087B (xx)
AT (2)	ATE537188T1 (xx)
AU (1)	AU2006249144B2 (xx)
BR (2)	BR122013001996B1 (xx)
CA (2)	CA2962819C (xx)
CR (1)	CR9519A (xx)
CY (1)	CY1122672T1 (xx)
DK (3)	DK1888641T3 (xx)
EC (1)	ECSP077910A (xx)
ES (3)	ES2379283T3 (xx)
HU (1)	HUE045710T2 (xx)
IL (3)	IL186941A (xx)
LT (1)	LT2949668T (xx)
MX (3)	MX363423B (xx)
NI (1)	NI200700291A (xx)
NO (2)	NO338568B1 (xx)
NZ (1)	NZ562695A (xx)
PL (3)	PL2949668T3 (xx)
PT (2)	PT2949668T (xx)
RU (2)	RU2464276C2 (xx)
SG (2)	SG10201708038QA (xx)
SI (3)	SI1888640T1 (xx)
TW (2)	TWI395755B (xx)
WO (2)	WO2006122787A1 (xx)
ZA (3)	ZA200709867B (xx)

Families Citing this family (352)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2005289809A (ja) *	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
US9321832B2 (en) *	2002-06-28	2016-04-26	Domantis Limited	Ligand
US9453251B2 (en)	2002-10-08	2016-09-27	Pfenex Inc.	Expression of mammalian proteins in Pseudomonas fluorescens
US9320792B2 (en)	2002-11-08	2016-04-26	Ablynx N.V.	Pulmonary administration of immunoglobulin single variable domains and constructs thereof
JP2006520584A (ja)	2002-11-08	2006-09-14	アブリンクスエン．ヴェー．	安定化単一ドメイン抗体
US20060034845A1 (en)	2002-11-08	2006-02-16	Karen Silence	Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
CA2574953A1 (en)	2004-07-26	2006-02-09	Dow Global Technolgies Inc.	Process for improved protein expression by strain engineering
EP3613767A1 (en)	2005-05-18	2020-02-26	Ablynx N.V.	Improved nanobodiestm against tumor cecrosis factor-alpha
DE102005023617A1 (de) *	2005-05-21	2006-11-23	Aspre Ag	Verfahren zum Mischen von Farben in einem Display
US20070269422A1 (en) *	2006-05-17	2007-11-22	Ablynx N.V.	Serum albumin binding proteins with long half-lives
US20100113339A1 (en) *	2006-09-08	2010-05-06	Ablynx N. V.	Serum albumin binding proteins with long half-lives
CA2666511A1 (en) *	2006-10-11	2008-04-17	Ablynx N.V.	Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and uses thereof
WO2008071685A1 (en) *	2006-12-13	2008-06-19	Ablynx N.V.	Polypeptides specific for complexes involved in receptor-mediated signaling, such as the il-6/il-6 receptor complex
AU2007331672A1 (en) *	2006-12-15	2008-06-19	Ablynx N.V.	Amino acid sequences that modulate the interaction between cells of the immune system
EP2514767A1 (en)	2006-12-19	2012-10-24	Ablynx N.V.	Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
EP2557090A3 (en)	2006-12-19	2013-05-29	Ablynx N.V.	Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
US9512236B2 (en)	2006-12-19	2016-12-06	Ablynx N.V.	Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2008074868A1 (en) *	2006-12-20	2008-06-26	Ablynx N.V.	Oral delivery of polypeptides
CA2678218A1 (en) *	2007-02-21	2008-08-28	Ablynx N.V.	Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CA2685326A1 (en)	2007-04-27	2008-11-06	Dow Global Technologies Inc.	Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en)	2007-04-27	2017-02-28	Pfenex, Inc.	Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CN101796072B (zh)	2007-05-24	2014-09-24	埃博灵克斯股份有限公司	用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
WO2009004066A2 (en)	2007-07-03	2009-01-08	Ablynx N.V.	Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
ES2667729T3 (es)	2007-09-26	2018-05-14	Ucb Biopharma Sprl	Fusiones de anticuerpos con doble especificidad
AU2008328781A1 (en)	2007-11-27	2009-06-04	Ablynx N.V.	Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
CA2717015A1 (en) *	2008-03-05	2009-09-11	Ablynx Nv	Novel antigen binding dimer-complexes, methods of making and uses thereof
GB0809069D0 (en)	2008-05-19	2008-06-25	Univ Leuven Kath	Gene signatures
CN102056945A (zh)	2008-04-07	2011-05-11	埃博灵克斯股份有限公司	针对Notch途径的单可变结构域
EP2268668A1 (en) *	2008-04-17	2011-01-05	Ablynx N.V.	Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US8444976B2 (en)	2008-07-02	2013-05-21	Argen-X B.V.	Antigen binding polypeptides
HUE033438T2 (en)	2008-09-26	2017-11-28	Ucb Biopharma Sprl	Biological products
CA2739352C (en) *	2008-10-29	2021-07-13	Wyeth Llc	Methods for purification of single domain antigen binding molecules
AU2013202856B2 (en) *	2008-10-29	2016-02-11	Ablynx N.V.	Formulations of single domain antigen binding molecules
US9393304B2 (en) *	2008-10-29	2016-07-19	Ablynx N.V.	Formulations of single domain antigen binding molecules
US9265834B2 (en) *	2009-03-05	2016-02-23	Ablynx N.V.	Stable formulations of polypeptides and uses thereof
EP2403873A1 (en)	2009-03-05	2012-01-11	Ablynx N.V.	Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
KR101470690B1 (ko)	2009-04-10	2014-12-10	아블린쓰 엔.브이.	Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드
EP3828201A1 (en)	2009-04-30	2021-06-02	Ablynx N.V.	Method for the production of domain antibodies
EP3205670A1 (en)	2009-06-05	2017-08-16	Ablynx N.V.	Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US9150640B2 (en)	2009-07-10	2015-10-06	Ablynx N.V.	Method for the production of variable domains
US20120244158A1 (en)	2009-09-03	2012-09-27	Ablynx N.V.	Stable formulations of polypeptides and uses thereof
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
UY32920A (es)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Moleculas de unión biespecíficas para la terapia anti-angiogénesis
UY32917A (es)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Moléculas de unión a dll-4
WO2011064382A1 (en)	2009-11-30	2011-06-03	Ablynx N.V.	Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US8962807B2 (en)	2009-12-14	2015-02-24	Ablynx N.V.	Single variable domain antibodies against OX40L, constructs and therapeutic use
WO2011083141A2 (en)	2010-01-08	2011-07-14	Ablynx Nv	Method for generation of immunoglobulin sequences by using lipoprotein particles
AU2011212442A1 (en)	2010-02-05	2012-08-09	Ablynx Nv	Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
US9120855B2 (en)	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
EP3501499B1 (en)	2010-02-11	2022-09-07	Ablynx NV	Methods and compositions for the preparation of aerosols
US20130012916A1 (en)	2010-02-11	2013-01-10	Glide Pharmaceutical Technologies Limited	Delivery of immunoglobulin variable domains and constructs thereof
CA2788275A1 (en)	2010-03-03	2011-09-09	Boehringer Ingelheim International Gmbh	Biparatopic abeta binding polypeptides
WO2011117423A1 (en)	2010-03-26	2011-09-29	Ablynx N.V.	Immunoglobulin single variable domains directed against cxcr7
US9556273B2 (en)	2010-03-29	2017-01-31	Vib Vzw	Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en)	2010-03-29	2015-08-11	Vib Vzw	Targeting and in vivo imaging of tumor-associated macrophages
EP3546483A1 (en)	2010-05-20	2019-10-02	Ablynx N.V.	Biological materials related to her3
WO2011161263A1 (en)	2010-06-25	2011-12-29	Ablynx Nv	Pharmaceutical compositions for cutaneous administration
JP2013536175A (ja) *	2010-07-16	2013-09-19	アブリンクスエン．ヴェー．	修飾された単一ドメイン抗原結合分子及びその使用
US20120225081A1 (en)	2010-09-03	2012-09-06	Boehringer Ingelheim International Gmbh	Vegf-binding molecules
EP2621953B1 (en)	2010-09-30	2017-04-05	Ablynx N.V.	Biological materials related to c-met
US11644471B2 (en)	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PL3279214T3 (pl)	2010-10-29	2025-03-24	Ablynx Nv	Sposób wytwarzania pojedynczych domen zmiennych immunoglobuliny
CU24111B1 (es)	2010-11-08	2015-08-27	Novartis Ag	Polipéptidos que se enlazan a cxcr2
CA2818969C (en)	2010-11-26	2020-04-14	Molecular Partners Ag	Improved n-terminal capping modules for designed ankyrin repeat proteins
JP6181040B2 (ja) *	2011-03-28	2017-08-16	アブリンクスエン．ヴェー．	二特異性抗ｃｘｃｒ７免疫グロブリン単一可変ドメイン
AU2012234282B2 (en)	2011-03-28	2015-07-16	Ablynx Nv	Method for producing solid formulations comprising immunoglobulin single variable domains
AU2012237287B2 (en) *	2011-03-30	2016-09-08	Ablynx Nv	Methods of treating immune disorders with single domain antibodies against TNF-alpha
US20130078247A1 (en)	2011-04-01	2013-03-28	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9534039B2 (en)	2011-05-09	2017-01-03	Ablynx N.V.	Method for the production of immunoglobulin single variable domains
WO2012163887A1 (en)	2011-05-27	2012-12-06	Ablynx Nv	Inhibition of bone resorption with rankl binding peptides
EP4350345A3 (en)	2011-06-23	2024-07-24	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
SI2723771T1 (sl)	2011-06-23	2019-12-31	Ablynx Nv	Proteini, ki vežejo serum albumin
SG10201605048XA (en) †	2011-06-23	2016-07-28	Ablynx Nv	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2944653A1 (en)	2011-06-23	2015-11-18	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
WO2012175740A1 (en)	2011-06-23	2012-12-27	Ablynx Nv	Immunoglobulin single variable domains directed against ige
JP2014530001A (ja)	2011-09-23	2014-11-17	テクノファージ，インベスティガサンエデセンボルビメントエムビオテクノロジア，エスエー	抗腫瘍壊死因子−α剤及びその使用
DK2747782T3 (en)	2011-09-23	2018-04-23	Ablynx Nv	Long-term inhibition of interleukin-6-mediated signal transmission
US9346884B2 (en)	2011-09-30	2016-05-24	Ablynx N.V.	Biological materials related to c-Met
JP6219287B2 (ja)	2011-09-30	2017-10-25	アブリンクスエン．ヴェー．	ｃ−Ｍｅｔに関連する生物学的物質
PH12021553014A1 (en)	2012-02-27	2022-09-05	Ablynx Nv	Cx3cr1-binding polypeptides
JP5970734B2 (ja)	2012-03-30	2016-08-17	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ａｎｇ２結合分子
WO2013167883A1 (en)	2012-05-07	2013-11-14	The University Court Of The University Of Aberdeen	Single domain binding molecule
US9328174B2 (en)	2012-05-09	2016-05-03	Novartis Ag	Chemokine receptor binding polypeptides
CN108524919A (zh)	2012-05-17	2018-09-14	延伸生物科学股份有限公司	用于改进的药物递送的载体
JP6411333B2 (ja)	2012-05-24	2018-10-24	ブイアイビーブイゼットダブリュＶｉｂＶｚｗ	腫瘍関連マクロファージのターゲティングおよびｉｎｖｉｖｏイメージング用抗マクロファージマンノース受容体単一可変ドメイン
RU2530553C2 (ru) *	2012-11-07	2014-10-10	Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ)	Рекомбинантное однодоменное антитело, способное специфически связывать фактор некроза опухолей человека, и его производные
US9315280B2 (en) *	2012-11-20	2016-04-19	Lockheed Martin Corporation	Heat pipe with axial wick
WO2014087010A1 (en)	2012-12-07	2014-06-12	Ablynx N.V.	IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
WO2017004144A1 (en)	2015-07-01	2017-01-05	Immunomedics, Inc.	Antibody-sn-38 immunoconjugates with a cl2a linker
JP6461808B2 (ja)	2012-12-17	2019-01-30	ラボラトワールフランセドゥフラクションマンエデバイオテクノロジーズＬａｂｏｒａｔｏｉｒｅＦｒａｎｃａｉｓＤｕＦｒａｃｔｉｏｎｎｅｍｅｎｔＥｔＤｅｓＢｉｏｔｅｃｈｎｏｌｏｇｉｅｓ	炎症および細菌感染症処置におけるモノクローナル抗体の使用
WO2014111550A1 (en)	2013-01-17	2014-07-24	Glaxosmithkline Intellectual Property Development Limited	Modified anti-serum albumin binding proteins
WO2014118297A1 (en)	2013-01-30	2014-08-07	Vib Vzw	Novel chimeric polypeptides for screening and drug discovery purposes
EP2953973B1 (en)	2013-02-05	2019-07-10	VIB vzw	Muscarinic acetylcholine receptor binding agents and uses thereof
TW201444870A (zh)	2013-02-13	2014-12-01	Lab Francais Du Fractionnement	高度半乳糖基化的抗ｈｅｒ２抗體及其用途
TW201444871A (zh)	2013-02-13	2014-12-01	Lab Francais Du Fractionnement	具有修飾的糖化作用之西妥昔單抗及其用途
TW201506041A (zh)	2013-02-13	2015-02-16	Lab Francais Du Fractionnement	高度半乳糖基化的抗腫瘤壞死因子阿爾法抗體及其用途
USRE48805E1 (en)	2013-03-06	2021-11-02	Vision Global Holdings Ltd.	Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
US9255262B2 (en)	2013-03-06	2016-02-09	Vision Global Holdings Ltd.	Albumin-binding arginine deminase and the use thereof
CN118028464A (zh)	2013-03-14	2024-05-14	儿童医学中心公司	Cd36鉴定癌症对象以用于治疗的用途
JP6499090B2 (ja)	2013-03-15	2019-04-10	ブイアイビーブイゼットダブリュＶｉｂＶｚｗ	心血管疾患において使用するための抗マクロファージマンノース受容体単一可変ドメイン
CN105531370A (zh)	2013-04-23	2016-04-27	阿伯丁大学理事会	治疗靶向特异性vnar结构域与icosl的分离
NL1040254C2 (en)	2013-05-17	2014-11-24	Ablynx Nv	Stable formulations of immunoglobulin single variable domains and uses thereof.
KR102665705B1 (ko)	2013-10-21	2024-05-14	다케다 파머수티컬 컴패니 리미티드	자가면역 질환의 진단 및 치료
JP6687525B2 (ja)	2014-01-30	2020-04-22	ブイアイビーブイゼットダブリュＶｉｂＶｚｗ	オピオイド受容体結合剤およびその使用
WO2015144852A1 (en) *	2014-03-26	2015-10-01	Delenex Therapeutics Ag	Binding members to tnf alpha
WO2015164717A1 (en)	2014-04-24	2015-10-29	Immusant, Inc.	Methods of diagnosis and treatment of celiac disease in children
KR20250099289A (ko)	2014-05-16	2025-07-01	아블린쓰 엔.브이.	개선된 면역글로불린 가변 도메인
HUE056738T2 (hu)	2014-05-16	2022-03-28	Ablynx Nv	Eljárás gyógyszer elleni antitestek, különösen kezelés kapcsán kialakuló gyógyszer elleni antitestek detektálására és/vagy mérésére
AU2015261536B2 (en)	2014-05-16	2020-05-07	Ablynx Nv	Improved immunoglobulin variable domains
US20170088896A1 (en)	2014-05-16	2017-03-30	Children's Hospital Medical Center d/b/a Cincinnati Children's Hospital, Medical Center	Methods for assessing responsiveness to asthma treatment based on vnn-1 expression and promoter methylation
NL2013661B1 (en)	2014-10-21	2016-10-05	Ablynx Nv	KV1.3 Binding immunoglobulins.
WO2016012363A1 (en)	2014-07-22	2016-01-28	Vib Vzw	Methods to select for agents that stabilize protein complexes
PT3204018T (pt)	2014-10-07	2021-11-12	Immunomedics Inc	Uso neoadjuvante de conjugados anticorpo-fármaco
US20170224758A1 (en)	2014-10-17	2017-08-10	The Broad Institute, Inc.	Compositions and methods of treating muscular dystrophy
WO2016065042A1 (en)	2014-10-22	2016-04-28	Extend Biosciences, Inc.	Therapeutic vitamin d conjugates
US9789197B2 (en)	2014-10-22	2017-10-17	Extend Biosciences, Inc.	RNAi vitamin D conjugates
WO2016065052A1 (en)	2014-10-22	2016-04-28	Extend Biosciences, Inc.	Insulin vitamin d conjugates
HRP20211889T1 (hr)	2014-10-23	2022-03-04	Singh Molecular Medicine, Llc	Antitijela sa jednom domenom usmjerena protiv intracelularnih antigena
US20170267784A1 (en)	2014-10-23	2017-09-21	Singh Molecular Medicine, Llc	Single domain antibodies directed against intracellular antigens
EP3230457B1 (en)	2014-12-09	2021-06-30	New York University	Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
CA2971278C (en)	2014-12-19	2023-09-19	Ablynx N.V.	Cysteine linked nanobody dimers
EP3242890B1 (en)	2015-01-08	2019-09-04	BioNTech SE	Agonistic tnf receptor binding agents
CN107438620A (zh)	2015-03-31	2017-12-05	韦斯夸尔德有限公司	多肽
IL254589B2 (en)	2015-03-31	2023-11-01	Vhsquared Ltd	A peptide structure with a protease-cleavable linker
IL254577B2 (en)	2015-03-31	2023-11-01	Vhsquared Ltd	polypeptides
CN107454904A (zh)	2015-04-02	2017-12-08	分子组合公司	对血清白蛋白具有结合特异性的经设计的锚蛋白重复结构域
CA2981543A1 (en)	2015-04-22	2016-10-27	Immunomedics, Inc.	Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
CN114920847A (zh)	2015-05-13	2022-08-19	埃博灵克斯股份有限公司	基于cd3反应性的t细胞募集多肽
HUE071467T2 (hu)	2015-05-13	2025-08-28	Ablynx Nv	TCR-alfa/-béta reaktivitásán alapulva T-sejtet toborzó polipeptidek
BR112017024899A2 (pt)	2015-05-21	2018-11-13	Harpoon Therapeutics, Inc.	proteínas de ligação trispecíficas e métodos de uso.
GB201510758D0 (en) *	2015-06-18	2015-08-05	Ucb Biopharma Sprl	Novel TNFa structure for use in therapy
US10973912B2 (en)	2015-06-29	2021-04-13	President And Fellows Of Harvard College	Treatment for myopathy
WO2017048872A1 (en)	2015-09-14	2017-03-23	Leukemia Therapeutics, LLC	Identification of novel diagnostics and therapeutics by modulating rhoh
TWI746473B (zh)	2015-11-02	2021-11-21	美商辛分子醫藥有限公司	針對細胞內抗原之單域抗體
NO2768984T3 (xx) *	2015-11-12	2018-06-09
AU2016353067B2 (en)	2015-11-13	2023-10-05	Sanford Research	Anti-BCMA polypeptides and proteins
RS62857B1 (sr)	2015-11-13	2022-02-28	Ablynx Nv	Unapređeni varijabilni domeni imunoglobulina koji vezuju serumski albumin
EA038179B1 (ru)	2015-11-18	2021-07-20	Мерк Шарп И Доум Корп.	Ctla4-связывающие вещества
UA121914C2 (uk)	2015-11-18	2020-08-10	Мерк Шарп І Доум Корп.	Молекула, що зв'язує pd1 і lag3
JP7046804B2 (ja)	2015-11-18	2022-04-04	アブリンクスエン．ヴェー．	改良された血清アルブミン結合剤
RU2755724C2 (ru)	2015-11-18	2021-09-20	Мерк Шарп И Доум Корп.	Pd1/ctla4-связывающие вещества
EP3380517B1 (en) *	2015-11-27	2021-08-04	Ablynx NV	Polypeptides inhibiting cd40l
US10597449B2 (en)	2015-12-04	2020-03-24	Boehringer Ingelheim International Gmbh	Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
GB201522394D0 (en) *	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibodies
US10465003B2 (en) *	2016-02-05	2019-11-05	Janssen Biotech, Inc.	Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JP7030704B2 (ja)	2016-02-05	2022-03-08	オリオニスバイオサイエンシズビーブイ	二重特異性シグナル伝達物質およびその使用
CN109069573B (zh)	2016-03-07	2022-04-05	弗拉芒区生物技术研究所	结合cd20的单结构域抗体
AU2017259876A1 (en)	2016-05-02	2018-10-25	Ablynx Nv	Treatment of RSV infection
CN109563141A (zh)	2016-05-13	2019-04-02	奥里尼斯生物科学公司	对非细胞结构的治疗性靶向
JP7101621B2 (ja)	2016-05-20	2022-07-15	ハープーンセラピューティクス，インク．	単一ドメイン血清アルブミン結合タンパク質
BR112018073761A2 (pt)	2016-05-20	2019-02-26	Harpoon Therapeutics, Inc.	proteínas de ligação ao cd3 de fragmento variável de cadeia única
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
US20190195866A1 (en)	2016-06-23	2019-06-27	Ablynx N.V.	Improved pharmacokinetic assays for immunoglobulin single variable domains
WO2018007442A1 (en)	2016-07-06	2018-01-11	Ablynx N.V.	Treatment of il-6r related diseases
WO2018029182A1 (en)	2016-08-08	2018-02-15	Ablynx N.V.	Il-6r single variable domain antibodies for treatment of il-6r related diseases
EP3512880A1 (en)	2016-09-15	2019-07-24	Ablynx NV	Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
EP3519438A1 (en)	2016-09-30	2019-08-07	VHsquared Limited	Compositions
CN117700549A (zh)	2016-11-16	2024-03-15	埃博灵克斯股份有限公司	能够结合CD123和TCRα/β的T细胞募集多肽
KR20190087539A (ko)	2016-11-23	2019-07-24	하푼 테라퓨틱스, 인크.	Psma 표적화 삼중특이성 단백질 및 사용 방법
WO2018098354A1 (en)	2016-11-23	2018-05-31	Harpoon Therapeutics, Inc.	Prostate specific membrane antigen binding protein
WO2018099968A1 (en)	2016-11-29	2018-06-07	Ablynx N.V.	Treatment of infection by respiratory syncytial virus (rsv)
KR20230061582A (ko) *	2016-12-07	2023-05-08	아블린쓰 엔.브이.	개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
GB201621907D0 (en)	2016-12-21	2017-02-01	Ucb Biopharma Sprl And Sanofi	Antibody epitope
CN107674122A (zh) *	2016-12-28	2018-02-09	天津天锐生物科技有限公司	一种识别人血清白蛋白的单域抗体
CN117285623A (zh)	2017-01-17	2023-12-26	埃博灵克斯股份有限公司	改进的血清白蛋白结合物
SG10202108973SA (en)	2017-01-17	2021-09-29	Ablynx Nv	Improved serum albumin binders
EP3577133A1 (en)	2017-02-06	2019-12-11	Orionis Biosciences NV	Targeted chimeric proteins and uses thereof
NZ756674A (en)	2017-02-16	2023-06-30	Sonnet Biotherapeutics Inc	Albumin binding domain fusion proteins
CN110573604A (zh)	2017-02-28	2019-12-13	非营利性组织佛兰芒综合大学生物技术研究所	用于口服蛋白质递送的工具和方法
EP3589662A4 (en)	2017-02-28	2020-12-30	Harpoon Therapeutics, Inc.	INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
CN110546506B (zh) *	2017-03-31	2023-04-04	埃博灵克斯股份有限公司	改进的免疫原性测定法
EP3621990A1 (en)	2017-05-11	2020-03-18	VIB vzw	Glycosylation of variable immunoglobulin domains
CA3063359A1 (en)	2017-05-12	2018-11-15	Harpoon Therapeutics, Inc.	Mesothelin binding proteins
CA3063362A1 (en)	2017-05-12	2018-11-15	Harpoon Therapeutics, Inc.	Msln targeting trispecific proteins and methods of use
MX2019014331A (es)	2017-05-31	2020-01-27	Boehringer Ingelheim Int	Polipeptidos que antagonizan la se?alizacion wnt en celulas tumorales.
KR20250005464A (ko)	2017-06-02	2025-01-09	메르크 파텐트 게엠베하	Adamts5, mmp13 및 아그레칸 결합성 폴리펩타이드
TWI811220B (zh)	2017-06-02	2023-08-11	比利時商艾伯林克斯公司	結合聚集蛋白聚糖之免疫球蛋白
US12129308B2 (en)	2017-06-02	2024-10-29	Merck Patent Gmbh	MMP13 binding immunoglobulins
RS66191B1 (sr)	2017-06-02	2024-12-31	Merck Patent Gmbh	Imunoglobulini koji vezuju adamts
CA3061053A1 (en)	2017-06-02	2018-12-06	Boehringer Ingelheim International Gmbh	Anti-cancer combination therapy
GB201710973D0 (en)	2017-07-07	2017-08-23	Avacta Life Sciences Ltd	Scaffold proteins
WO2019016237A1 (en)	2017-07-19	2019-01-24	Vib Vzw	AGENTS FOR CONNECTING TO SERUM ALBUMIN
KR102425983B1 (ko)	2017-10-13	2022-07-29	하푼 테라퓨틱스, 인크.	삼중특이적 단백질 및 사용 방법
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
US11873347B2 (en)	2017-10-31	2024-01-16	Vib Vzw	Antigen-binding chimeric proteins and methods and uses thereof
WO2019133827A1 (en) *	2017-12-29	2019-07-04	Board Of Regents, The University Of Texas System	Antimicrobial nanobodies
EP3743448A4 (en)	2018-01-26	2021-11-03	Orionis Biosciences, Inc.	XCR1 BINDING AGENTS AND USES THEREOF
EP3749295A4 (en)	2018-02-05	2022-04-27	Orionis Biosciences, Inc.	FIBROBLAST BINDING AGENTS AND USES THEREOF
WO2019155041A1 (en)	2018-02-12	2019-08-15	Vib Vzw	Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019165105A1 (en) *	2018-02-26	2019-08-29	The Board Of Trustees Of The Leland Stanford Junior University	Ligands of the urokinase receptor and their use in treating, detecting, and imaging cancer
EP3758742A1 (en)	2018-03-01	2021-01-06	Vrije Universiteit Brussel	Human pd-l1-binding immunoglobulins
US12123881B2 (en)	2018-04-20	2024-10-22	Unm Rainforest Innovations	Rap1-Gtp, Rac1-GTP and FMS-like tyrosine kinase 3 ligand (FLT3-L) as biomarkers for early detection of sepsis
BR112020023330A2 (pt)	2018-05-14	2021-04-20	Harpoon Therapeutics, Inc.	porção de ligação para ativação condicional de moléculas de imunoglobulina
CN110613838A (zh) *	2018-06-19	2019-12-27	姜石松	增强细胞通透性的多肽及其应用
DE102018122275A1 (de) *	2018-09-12	2020-03-12	Osram Opto Semiconductors Gmbh	Lichtemittierendes bauteil und verfahren zum betreiben eines lichtemittierenden bauteils
US12195544B2 (en)	2018-09-21	2025-01-14	Harpoon Therapeutics, Inc.	EGFR binding proteins and methods of use
EP3856771A4 (en)	2018-09-25	2022-06-29	Harpoon Therapeutics, Inc.	Dll3 binding proteins and methods of use
EP3636657A1 (en)	2018-10-08	2020-04-15	Ablynx N.V.	Chromatography-free antibody purification method
CN111138537B (zh) *	2018-11-06	2021-07-09	瑞阳(苏州)生物科技有限公司	一种抗人血清白蛋白抗体片段、制备方法和应用
CN111138536B (zh) *	2018-11-06	2021-07-09	瑞阳(苏州)生物科技有限公司	抗人血清白蛋白单域抗体的制备及其应用
WO2020097350A1 (en)	2018-11-08	2020-05-14	Orionis Biosciences, Inc.	Modulation of dendritic cell lineages
GB201818460D0 (en) *	2018-11-13	2018-12-26	Crescendo Biologics Ltd	Single domain antibodies that bind human serum albumin
CN112830967B (zh) *	2019-01-10	2022-06-24	瑞阳(苏州)生物科技有限公司	抗hsa单域抗体及其融合蛋白的亲和层析纯化方法
CN109627334B (zh) *	2019-01-29	2020-07-17	康元医疗科技(大连)有限公司	一种纳米抗体、以该纳米抗体为配基的吸附剂及其用途
GB201901306D0 (en)	2019-01-30	2019-03-20	Immunocore Ltd	Multi-domain binding molecules
US20200308276A1 (en)	2019-03-29	2020-10-01	Boehringer Ingelheim International Gmbh	Anticancer combination therapy
JP2022526166A (ja)	2019-03-29	2022-05-23	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	抗癌併用療法
WO2020221768A1 (en)	2019-04-29	2020-11-05	Confo Therapeutics N.V.	Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs
WO2020221888A1 (en)	2019-04-30	2020-11-05	Vib Vzw	Cystic fibrosis transmembrane conductance regulator stabilizing agents
KR20220008866A (ko)	2019-05-14	2022-01-21	하푼 테라퓨틱스, 인크.	EpCAM 결합 단백질 및 사용 방법
US20220220197A1 (en)	2019-05-28	2022-07-14	Vib Vzw	Cancer Treatment by Targeting Plexins in the Immune Compartment
EP3976067A1 (en)	2019-05-28	2022-04-06	Vib Vzw	Cd8+ t-cells lacking plexins and their application in cancer treatment
CA3138805A1 (en)	2019-06-04	2020-12-10	Johannes Schilling	Designed ankyrin repeat domain with improved stability
US20220242945A1 (en)	2019-06-21	2022-08-04	Sorriso Pharmaceuticals, Inc.	Polypeptides
AU2020294980A1 (en)	2019-06-21	2022-02-17	Sorriso Pharmaceuticals, Inc.	Polypeptides
WO2020254828A1 (en)	2019-06-21	2020-12-24	Vhsquared Limited	Compositions
TWI844709B (zh)	2019-07-31	2024-06-11	美商美國禮來大藥廠	鬆弛素(relaxin)類似物及其使用方法
CN112409480B (zh) *	2019-08-20	2024-08-27	四川科伦博泰生物医药股份有限公司	结合血清白蛋白的蛋白及其用途
WO2021039574A1 (ja) *	2019-08-23	2021-03-04	株式会社カネカ	Ｏ結合型糖鎖修飾が抑制された重鎖抗体
CN115947846A (zh)	2019-09-12	2023-04-11	普米斯生物技术(珠海)有限公司	一种抗pd-l1纳米抗体及其衍生物和用途
CN110642946A (zh) *	2019-09-30	2020-01-03	中国药科大学	一种人源化纳米抗体及其制备方法
TW202128775A (zh)	2019-10-16	2021-08-01	英商阿法克塔生命科學有限公司	PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
US20220380456A1 (en)	2019-10-21	2022-12-01	Vib Vzw	Nanodisc-specific antigen-binding chimeric proteins
CN112746331A (zh) *	2019-10-29	2021-05-04	安升（上海）医药科技有限公司	半衰期延长的药物及其文库、以及制备方法和应用
WO2021095031A2 (en)	2019-11-11	2021-05-20	Ibi-Ag Innovative Bio Insecticides Ltd.	Insect control nanobodies and uses thereof
WO2021105438A1 (en)	2019-11-27	2021-06-03	Vib Vzw	Positive allosteric modulators of the calcium-sensing receptor
WO2021110816A1 (en)	2019-12-06	2021-06-10	Ablynx Nv	POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23
MX2022006881A (es) *	2019-12-06	2022-07-11	Ablynx Nv	Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l.
TWI861302B (zh)	2019-12-09	2024-11-11	比利時商艾伯霖克斯公司	包含靶向il-13及tslp之免疫球蛋白單可變域的多肽
GB201918279D0 (en)	2019-12-12	2020-01-29	Vib Vzw	Glycosylated single chain immunoglobulin domains
CN110988361B (zh) *	2019-12-13	2020-09-18	山东民康生物科技有限公司	人血清白蛋白去除试剂盒
US20240027467A1 (en)	2019-12-20	2024-01-25	Vib Vzw	Nanobody Exchange Chromatography
CN112300289B (zh) *	2019-12-30	2022-06-10	中国药科大学	RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用
US12403175B2 (en)	2020-01-08	2025-09-02	argenx BV	Methods for treating pemphigus disorders
WO2021140205A1 (en)	2020-01-10	2021-07-15	Confo Therapeutics N.V.	Methods for generating antibodies and antibody fragments and libraries comprising same
WO2021156490A2 (en)	2020-02-06	2021-08-12	Vib Vzw	Corona virus binders
KR20220144841A (ko)	2020-02-21	2022-10-27	하푼 테라퓨틱스, 인크.	Flt3 결합 단백질 및 사용 방법
EP4110794A1 (en)	2020-02-25	2023-01-04	Vib Vzw	Leucine-rich repeat kinase 2 allosteric modulators
JP7754510B2 (ja) *	2020-03-06	2025-10-15	ユニバーシティオブピッツバーグ－オブザコモンウェルスシステムオブハイヤーエデュケイション	血清アルブミン結合ナノボディ組成物、及びその使用方法
JP2023523600A (ja)	2020-04-22	2023-06-06	マブウェル（シャンハイ）バイオサイエンスカンパニーリミテッド	ヒトプログラム細胞死リガンド１（ｐｄ－ｌ１）を標的とする単一可変ドメイン抗体およびその誘導体
WO2021229104A1 (en)	2020-05-15	2021-11-18	Université de Liège	Anti-cd38 single-domain antibodies in disease monitoring and treatment
GB202101299D0 (en)	2020-06-09	2021-03-17	Avacta Life Sciences Ltd	Diagnostic polypetides and methods
WO2022003156A1 (en)	2020-07-02	2022-01-06	Oncurious Nv	Ccr8 non-blocking binders
CN116284374A (zh) *	2020-08-14	2023-06-23	上海洛启生物医药技术有限公司	非pH依赖性长效型抗血清白蛋白纳米抗体及其应用
CN114106190B (zh) *	2020-08-31	2025-04-08	普米斯生物技术(珠海)有限公司	一种抗vegf/pd-l1双特异性抗体及其用途
EP4216943A1 (en)	2020-09-24	2023-08-02	Vib Vzw	Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en)	2020-09-24	2022-03-31	Vib Vzw	Biomarker for anti-tumor therapy
TW202229338A (zh)	2020-09-25	2022-08-01	比利時商艾伯霖克斯公司	包含靶向ｉｌ－１３和ｏｘ４０ｌ的免疫球蛋白單可變結構域的多肽
WO2022089435A1 (en) *	2020-10-27	2022-05-05	Beijing Ql Biopharmaceutical Co., Ltd.	Fusion proteins of gdf15 and use thereof
WO2022098743A1 (en)	2020-11-03	2022-05-12	Indi Molecular, Inc.	Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
WO2022098745A1 (en)	2020-11-03	2022-05-12	Indi Molecular, Inc.	Compositions, delivery systems, and methods useful in tumor therapy
WO2022117569A1 (en)	2020-12-02	2022-06-09	Oncurious Nv	A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2022117572A2 (en)	2020-12-02	2022-06-09	Oncurious Nv	An ltbr agonist in combination therapy against cancer
MX2023007299A (es)	2020-12-18	2023-07-04	Ablynx Nv	Polipeptidos de reclutamiento de celulas t basados en la reactividad de tcr alfa/beta.
TW202239763A (zh)	2020-12-18	2022-10-16	比利時商艾伯霖克斯公司	包含靶向ＩＬ－６和ＴＮＦ－α的免疫球蛋白單可變結構域的多肽
AU2021399955A1 (en)	2020-12-18	2023-08-03	Ablynx Nv	Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
GB202020502D0 (en)	2020-12-23	2021-02-03	Vib Vzw	Antibody composistion for treatment of corona virus infection
EP4267617A1 (en)	2020-12-24	2023-11-01	Vib Vzw	Human ccr8 binders
WO2022136650A1 (en)	2020-12-24	2022-06-30	Oncurious Nv	Murine cross-reactive human ccr8 binders
CA3206124A1 (en)	2020-12-24	2022-06-30	Vib Vzw	Non-blocking human ccr8 binders
CN117794566A (zh)	2021-02-05	2024-03-29	Vib研究所	沙贝病毒结合剂
AU2022216460A1 (en)	2021-02-05	2023-09-21	Universiteit Gent	Sarbecovirus binders
EP4294407A1 (en)	2021-02-17	2023-12-27	Vib Vzw	Inhibition of slc4a4 in the treatment of cancer
US20250263490A1 (en)	2021-02-19	2025-08-21	Vib Vzw	Cation-Independent Mannose-6-Phosphate Receptor Binders
WO2022199804A1 (en)	2021-03-24	2022-09-29	Vib Vzw	Nek6 inhibition to treat als and ftd
WO2022234003A1 (en)	2021-05-07	2022-11-10	Avacta Life Sciences Limited	Cd33 binding polypeptides with stefin a protein
US20240261446A1 (en)	2021-05-17	2024-08-08	Université de Liège	Anti-cd38 single domain antibodies in disease monitoring and treatment
US20240287501A1 (en)	2021-06-23	2024-08-29	Vib Vzw	Means and Methods for Selection of Specific Binders
US20240343811A1 (en)	2021-06-29	2024-10-17	Shandong Simcere Biopharmacutical Co., Ltd.	Cd16 antibody and use thereof
CN116635402B (zh) *	2021-07-14	2024-03-15	北京质肽生物医药科技有限公司	用于代谢病症的融合多肽
CN113527502B (zh) *	2021-07-20	2023-01-17	福建医科大学	一种用于治疗类风湿性关节炎的纳米抗体重组蛋白
WO2023016828A2 (en)	2021-07-30	2023-02-16	Vib Vzw	Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
WO2023006040A1 (zh)	2021-07-30	2023-02-02	江苏先声药业有限公司	抗pvrig/抗tigit双特异性抗体和应用
US20250243277A1 (en)	2021-10-07	2025-07-31	Avacta Life Sciences Limited	Pd-l1 binding affimers
EP4412711A1 (en)	2021-10-07	2024-08-14	Avacta Life Sciences Limited	Serum half-life extended pd-l1 binding polypeptides
JP2024541668A (ja)	2021-12-03	2024-11-08	山▲東▼先声生物制▲薬▼有限公司	抗ｂｃｍａナノ抗体及びその応用
CN113912730B (zh) *	2021-12-14	2022-03-04	北京科诺信诚科技有限公司	缓释的抗FcRn抗体或抗原结合片段及其应用
EP4448574A1 (en)	2021-12-17	2024-10-23	Ablynx N.V.	Polypeptides comprising immunoglobulin single variable domains targeting tcralphabeta, cd33 and cd123
US20250145705A1 (en)	2021-12-31	2025-05-08	Shandong Simcere Biopharmaceutical Co., Ltd.	Gprc5d antibody and application thereof
WO2023135198A1 (en)	2022-01-12	2023-07-20	Vib Vzw	Human ntcp binders for therapeutic use and liver-specific targeted delivery
WO2023148397A1 (en)	2022-02-07	2023-08-10	Vib Vzw	Engineered stabilizing aglycosylated fc-regions
KR102902533B1 (ko)	2022-02-10	2025-12-22	주식회사 아피셀테라퓨틱스	Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도
CN116925215A (zh) *	2022-03-31	2023-10-24	普米斯生物技术(珠海)有限公司	抗血清白蛋白纳米抗体及其衍生物
EP4508082A1 (en)	2022-04-13	2025-02-19	Vib Vzw	An ltbr agonist in combination therapy against cancer
WO2023218243A1 (en)	2022-05-12	2023-11-16	Avacta Life Sciences Limited	Lag-3/pd-l1 binding fusion proteins
WO2023222825A1 (en)	2022-05-18	2023-11-23	Vib Vzw	Sarbecovirus spike s2 subunit binders
CN115028719B (zh) *	2022-05-27	2023-01-13	深圳市人民医院	血清白蛋白结合纳米抗体及其制备方法与应用
EP4538294A1 (en)	2022-06-06	2025-04-16	Shandong Simcere Biopharmaceutical Co., Ltd.	Multi-specific antibody targeting bcma, gprc5d and t cells and application thereof
AU2023290487A1 (en)	2022-06-14	2025-01-30	Ablynx Nv	Immunoglobulin single variable domains targeting t cell receptor
WO2023242372A1 (en)	2022-06-15	2023-12-21	argenx BV	Fcrn/hsa binding molecules and methods of use
WO2024003873A1 (en) *	2022-06-30	2024-01-04	Intrexon Actobiotics Nv D/B/A Precigen Actobio	Single variable domain antibodies against tumor necrosis factor-alpha
US20250304677A1 (en)	2022-07-04	2025-10-02	Vib Vzw	Blood-Cerebrospinal Fluid Barrier Crossing Antibodies
AU2023313033A1 (en)	2022-07-27	2025-03-13	Ablynx Nv	Polypeptides binding to a specific epitope of the neonatal fc receptor
AU2023326586A1 (en)	2022-08-17	2025-02-13	Institut National de la Santé et de la Recherche Médicale	Improved anti-albumin nanobodies and their uses
EP4594348A1 (en)	2022-09-27	2025-08-06	Vib Vzw	Antivirals against human parainfluenza virus
AU2023353057A1 (en)	2022-09-30	2025-05-01	Extend Biosciences, Inc.	Long-acting parathyroid hormone
WO2024083843A1 (en)	2022-10-18	2024-04-25	Confo Therapeutics N.V.	Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
CN120322456A (zh)	2022-10-28	2025-07-15	嘉和生物药业有限公司	新型抗ctla4抗体
EP4619156A1 (en)	2022-11-15	2025-09-24	Imec VZW	Method and system for droplet manipulation
EP4634214A1 (en)	2022-12-15	2025-10-22	Aarhus Universitet	Synthetic activation of multimeric transmembrane receptors
US20240415974A1 (en)	2022-12-23	2024-12-19	Ablynx N.V.	Protein-based conjugation carriers
CN120529914A (zh)	2023-01-09	2025-08-22	奥德赛治疗股份有限公司	抗tnfr2抗原结合蛋白及其用途
KR20250135288A (ko) *	2023-01-18	2025-09-12	베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드	융합 폴리펩타이드의 액체 약학 조성물 및 이의 사용 방법
KR20250136390A (ko)	2023-01-20	2025-09-16	베링거 인겔하임 인터내셔날 게엠베하	IL-12 Fc 융합 단백질
EP4655324A1 (en)	2023-01-27	2025-12-03	Vib Vzw	Cd163-binding conjugates
WO2024156881A1 (en)	2023-01-27	2024-08-02	Vib Vzw	CD8b-BINDING POLYPEPTIDES
KR20250151445A (ko)	2023-02-17	2025-10-21	아블린쓰 엔.브이.	신생아 fc 수용체에 결합하는 폴리펩티드
WO2024175787A1 (en)	2023-02-24	2024-08-29	Vrije Universiteit Brussel	Anti-inflammatory pannexin 1 channel inhibitors
CN121263437A (zh)	2023-03-14	2026-01-02	奥德赛治疗股份有限公司	抗cd25抗原结合蛋白及其用途
AU2024236537A1 (en)	2023-03-14	2025-09-04	Aarhus Universitet	Genetically altered nfr5 receptor kinases
FR3147278A1 (fr)	2023-03-31	2024-10-04	Avacta Life Sciences Limited	Polypeptides de liaison au tnfr2 et procedes d'utilisation
CN121013863A (zh)	2023-03-31	2025-11-25	艾菲赛尔治疗株式会社	Tnfr2结合多肽及使用方法
WO2024208816A1 (en)	2023-04-03	2024-10-10	Vib Vzw	Blood-brain barrier crossing antibodies
WO2024226410A1 (en)	2023-04-24	2024-10-31	Merck Sharp & Dohme Llc	Trop2 binders and conjugates thereof
WO2024231348A1 (en)	2023-05-11	2024-11-14	Vib Vzw	Slc4a4/nbce1 inhibitors
AR132699A1 (es)	2023-05-17	2025-07-23	Odyssey Therapeutics Inc	Anticuerpos de dominio único modificados
WO2024240162A1 (en)	2023-05-23	2024-11-28	Shanghai Allygen Biologics Co., Ltd.	Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
WO2024261235A1 (en)	2023-06-22	2024-12-26	Ablynx Nv	Chimeric proteins for modulating cytokine receptor activity
WO2024261344A1 (en)	2023-06-23	2024-12-26	Vib Vzw	Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
AU2024308381A1 (en)	2023-06-29	2025-11-20	Odyssey Therapeutics, Inc.	Anti-trailr2 antigen-binding proteins and uses thereof
EP4483951A1 (en)	2023-06-30	2025-01-01	Université de Liège	Single-domain antibody for inhibition of neutrophil elastase activity
AR133188A1 (es)	2023-07-05	2025-09-03	Ablynx Nv	ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
TW202521562A (zh)	2023-08-11	2025-06-01	美商默沙東有限責任公司	單價介白素-12(IL-12) 異二聚體Fc蛋白
TW202525843A (zh)	2023-09-04	2025-07-01	法商賽諾菲公司	用於治療表現磷脂醯肌醇蛋白聚糖-3之腫瘤的多肽
TW202532432A (zh)	2023-09-22	2025-08-16	比利時商艾伯霖克斯公司	二及多價白蛋白結合劑
TW202530265A (zh)	2023-10-13	2025-08-01	美商奧迪希治療公司	抗cdh17抗原結合蛋白及其用途
WO2025090840A1 (en) *	2023-10-27	2025-05-01	Rutgers, The State University Of New Jersey	Antigen binding molecules targeting tnf-alpha
WO2025093683A1 (en)	2023-11-03	2025-05-08	Neuvasq Biotechnologies Sa	Wnt7 signaling agonists
AR134267A1 (es)	2023-11-08	2025-12-17	Sanofi Sa	Degradador lisosómico basado en cd25 y usos del mismo
WO2025109176A1 (en)	2023-11-22	2025-05-30	Exevir Bio Bv	Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
WO2025114529A1 (en)	2023-12-01	2025-06-05	Ablynx Nv	Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
WO2025125577A1 (en)	2023-12-14	2025-06-19	Vib Vzw	Antibodies against influenza b virus
WO2025133166A1 (en)	2023-12-22	2025-06-26	Ablynx Nv	Protein-based carriers for site-specific amine conjugation
TW202543670A (zh)	2023-12-22	2025-11-16	比利時商艾伯霖克斯公司	用於核內投予之基於蛋白質的接合載劑
US12134635B1 (en)	2023-12-29	2024-11-05	Sonnet BioTherapeutics, Inc.	Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025147862A1 (zh) *	2024-01-09	2025-07-17	上海洛启生物医药技术有限公司	血清白蛋白结合分子及其应用
WO2025154056A1 (en)	2024-01-21	2025-07-24	Ibi-Ag Innovative Bio Insecticides Ltd.	Anti-insect cda nanobodies and uses thereof
WO2025154058A1 (en)	2024-01-21	2025-07-24	Ibi-Ag Innovative Bio Insecticides Ltd.	Anti-insect hsp70 nanobodies and uses thereof
WO2025160546A1 (en)	2024-01-26	2025-07-31	The Johns Hopkins University	Dendrimer conjugate compositions for intracellular delivery of antibodies and antibody fragments
WO2025181155A1 (en)	2024-02-26	2025-09-04	Vib Vzw	Human beta-glucocerebrosidase binders and uses thereof
GB202403780D0 (en)	2024-03-15	2024-05-01	Avacta Life Sciences Ltd	Polypeptides and methods for detecting and quantifying small molecules
WO2025196308A1 (en)	2024-03-22	2025-09-25	Vib Vzw	Means and methods for displaying fc-containing proteins on cells and selection thereof
WO2025217240A1 (en)	2024-04-10	2025-10-16	Odyssey Therapeutics, Inc.	Anti-tnfr2 antigen-binding proteins and uses thereof
US12459994B2 (en)	2024-04-12	2025-11-04	Paragon Therapeutics, Inc.	Albumin binding proteins and methods of use
WO2025219231A1 (en)	2024-04-15	2025-10-23	Vib Vzw	Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025255558A2 (en)	2024-06-07	2025-12-11	Odyssey Therapeutics, Inc.	Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en)	2024-06-07	2025-12-11	Odyssey Therapeutics, Inc.	Antigen-binding proteins against serum albumin and uses thereof
WO2026006708A2 (en)	2024-06-27	2026-01-02	Odyssey Therapeutics, Inc.	Anti-cd25 antigen-binding proteins and uses thereof
WO2026006809A1 (en)	2024-06-27	2026-01-02	Odyssey Therapeutics, Inc.	Multispecific molecules binding tnfr2 and cd25 and uses thereof
WO2026008664A1 (en)	2024-07-01	2026-01-08	Vib Vzw	Allosteric modulators of inhibitory immune receptor complexes

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US460167A (en)		1891-09-29		Car-mover
DE321017C (xx)	1917-05-15	1920-05-11	Aloysius Petrus Van Leuven
SE307996B (xx)	1965-11-30	1969-01-27	Asea Ab
US4352678A (en)	1978-10-02	1982-10-05	Lever Brothers Company	Thickened abrasive bleaching compositions
US4722896A (en)	1981-01-26	1988-02-02	The Beth Israel Hospital Association	Method for affinity purification of hybridoma antibodies
US4559157A (en)	1983-04-21	1985-12-17	Creative Products Resource Associates, Ltd.	Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr)	1983-08-30	1985-04-24	Oreal	Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5672347A (en)	1984-07-05	1997-09-30	Genentech, Inc.	Tumor necrosis factor antagonists and their use
US4735898A (en)	1985-07-16	1988-04-05	The University Of Virginia Alumini Patents Foundation	Monoclonal antibodies and method of identifying species using the same
JPS62175426A (ja)	1986-01-27	1987-08-01	Kazufumi Shimizu	抗体及びこれを有効成分とするスプレ−剤
ATE122238T1 (de)	1987-06-10	1995-05-15	Dana Farber Cancer Inst Inc	Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen.
US4820508A (en)	1987-06-23	1989-04-11	Neutrogena Corporation	Skin protective composition
US4992478A (en)	1988-04-04	1991-02-12	Warner-Lambert Company	Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en)	1988-09-12	1990-07-03	University Of New York	Treatment of damaged bone marrow and dosage units therefor
WO1990005144A1 (en)	1988-11-11	1990-05-17	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
SE509359C2 (sv)	1989-08-01	1999-01-18	Cemu Bioteknik Ab	Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6451983B2 (en)	1989-08-07	2002-09-17	Peptech Limited	Tumor necrosis factor antibodies
AU640400B2 (en)	1989-08-07	1993-08-26	Peptide Technology Ltd.	Tumour necrosis factor binding ligands
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
NZ234246A (en)	1990-03-16	1992-06-26	Flexitech Consulting Services	Form filling powdered material packages using interleaved plastics/paper packaging
GB9016299D0 (en)	1990-07-25	1990-09-12	Brien Caroline J O	Binding substances
CA2090126C (en)	1990-08-02	2002-10-22	John W. Schrader	Methods for the production of proteins with a desired function
US5656272A (en)	1991-03-18	1997-08-12	New York University Medical Center	Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
JPH06508371A (ja)	1991-06-21	1994-09-22	ユニバーシティーオブシンシナティ	経口投与できる治療用タンパク質及びその製法
WO1993006213A1 (en)	1991-09-23	1993-04-01	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
CA2507749C (en)	1991-12-13	2010-08-24	Xoma Corporation	Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en)	1991-12-13	1999-02-09	Xoma Corporation	Modified antibody variable domains
DE69325738T2 (de)	1992-04-28	2000-01-27	Sumitomo Rubber Industry Ltd., Kobe	Fester Golfball
CA2137558A1 (en)	1992-07-17	1994-02-03	Wayne A. Marasco	Method of intracellular binding of target molecules
EP0584421A1 (en)	1992-08-21	1994-03-02	Cécile Casterman	Immunoglobulins devoid of light chains
ATE420178T1 (de)	1992-08-21	2009-01-15	Univ Bruxelles	Immunoglobuline ohne leichtkette
ES2121907T3 (es)	1992-08-28	1998-12-16	Bayer Ag	Uso de anticuerpos monoclonales anti-tnf para el tratamiento de meningitis bacterianas.
US5741488A (en)	1992-10-08	1998-04-21	The Kennedy Institute For Rheumatology	Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies
DK0672142T3 (da)	1992-12-04	2001-06-18	Medical Res Council	Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
AU6268894A (en)	1993-02-22	1994-09-14	Alza Corporation	Compositions for oral delivery of active agents
EP0698097B1 (en)	1993-04-29	2001-08-16	Unilever N.V.	Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US6838254B1 (en)	1993-04-29	2005-01-04	Conopco, Inc.	Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
GB9311454D0 (en)	1993-06-03	1993-07-21	Agricultural & Food Res	Pharmaceutical compositions
WO1994029469A2 (en)	1993-06-07	1994-12-22	Vical Incorporated	Plasmids suitable for gene therapy
WO1994029457A2 (en)	1993-06-09	1994-12-22	Unilever N.V.	Process for producing fusion proteins comprising scfv fragments by a transformed mould
JPH09501055A (ja)	1993-07-30	1997-02-04	ユニバーシティオブメディシンアンドデンティストリーオブニュージャージー	初代リンパ球への効率的遺伝子転移
FR2708622B1 (fr)	1993-08-02	1997-04-18	Raymond Hamers	Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US6091639A (en)	1993-08-27	2000-07-18	Kabushiki Kaisha Toshiba	Non-volatile semiconductor memory device and data programming method
CA2169298A1 (en)	1993-09-10	1995-03-16	Martin Chalfie	Uses of green fluorescent protein
WO1995021191A1 (en)	1994-02-04	1995-08-10	William Ward	Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
JPH10501681A (ja)	1994-02-22	1998-02-17	ダナ−ファーバーキャンサーインスティチュート	核酸送達システムならびにその合成および使用方法
US5625048A (en)	1994-11-10	1997-04-29	The Regents Of The University Of California	Modified green fluorescent proteins
AU4964896A (en)	1995-01-19	1996-08-07	Research Foundation Of The State University Of New York, The	Genes encoding an insect calcium channel
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5693492A (en)	1995-05-05	1997-12-02	Merck & Co., Inc.	DNA encoding glutamate gated chloride channels
AU723325B2 (en)	1995-06-23	2000-08-24	President And Fellows Of Harvard College	Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
DE69604298T2 (de)	1995-09-22	2000-05-18	Bioimage A/S, Soeborg	Varianten des grünen fluoreszenzproteins, gfp
US7368111B2 (en)	1995-10-06	2008-05-06	Cambridge Antibody Technology Limited	Human antibodies specific for TGFβ2
US6027881A (en)	1996-05-08	2000-02-22	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
CA2258518C (en)	1996-06-27	2011-11-22	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Recognition molecules interacting specifically with the active site or cleft of a target molecule
US6124128A (en)	1996-08-16	2000-09-26	The Regents Of The University Of California	Long wavelength engineered fluorescent proteins
US6417337B1 (en)	1996-10-31	2002-07-09	The Dow Chemical Company	High affinity humanized anti-CEA monoclonal antibodies
WO1998021355A1 (en)	1996-11-15	1998-05-22	Life Technologies, Inc.	Mutants of green fluorescent protein
EP1027073A2 (en)	1996-11-19	2000-08-16	Sangstat Medical Corporation	Enhanced effects for hapten conjugated therapeutics
US6262238B1 (en)	1997-01-14	2001-07-17	Roche Diagnostic, Gmbh	Process for modifying the stability of antibodies
US6329516B1 (en)	1997-04-28	2001-12-11	Fmc Corporation	Lepidopteran GABA-gated chloride channels
FR2766826B1 (fr)	1997-08-04	2001-05-18	Pasteur Institut	Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
US5895466A (en)	1997-08-19	1999-04-20	At&T Corp	Automated natural language understanding customer service system
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
AU2152299A (en)	1997-10-27	1999-05-24	Unilever Plc	Multivalent antigen-binding proteins
AU3596599A (en)	1998-01-26	1999-08-09	Unilever Plc	Method for producing antibody fragments
CA2321199A1 (en)	1998-02-19	1999-08-26	William A. Brady	Compositions and methods for regulating lymphocyte activation
EP0967284A1 (en)	1998-05-28	1999-12-29	Pfizer Limited	Phosphodiesterases
ATE232298T1 (de)	1998-07-06	2003-02-15	Euroscreen Sa	Bioluminenztest für agonisten oder antagonisten eines kalzium-gekuppelten-rezeptors
JP2002522780A (ja)	1998-08-13	2002-07-23	ユー．エス．ゲノミクス	ポリマーの光学的な特性決定
GB9824632D0 (en)	1998-11-10	1999-01-06	Celltech Therapeutics Ltd	Biological compounds
IL127127A0 (en)	1998-11-18	1999-09-22	Peptor Ltd	Small functional units of antibody heavy chain variable regions
EP1141711A1 (en)	1999-01-05	2001-10-10	Unilever Plc	Binding of antibody fragments to solid supports
WO2000043507A1 (en)	1999-01-19	2000-07-27	Unilever Plc	Method for producing antibody fragments
WO2000046383A2 (en)	1999-02-05	2000-08-10	Rijksuniversiteit Leiden	Method of modulating metabolite biosynthesis in recombinant cells
US6617122B1 (en)	1999-03-15	2003-09-09	Xenon Genetics, Inc.	Process for identifying modulators of ABC1 activity
BR0009866A (pt)	1999-04-22	2002-01-08	Unilever Nv	Método de inibição de infecção viral, uso de uma proteìna de ligação de antìgeno monovalente, produto alimentìcio, composição farmacêutica ou cosmética, proteìna de ligação de antìgeno monovalente, sequência de nucleotìdeos, vetor de expressão, célula hospedeira, e, métodos de seleção e de indentificação de uma proteìna de ligação de antìgeno
CA2375033A1 (en)	1999-05-27	2000-12-07	Max-Delbruck-Centrum Fur Molekulare Medizin	Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides
MXPA01013175A (es)	1999-06-18	2002-06-04	Cv Therapeutics Inc	Composiciones y metodos para incrementar el flujo del colesterol y elevar hdl utilizando un cassette de enlace atp transportador de proteina abc1.
WO2001009300A2 (en)	1999-08-02	2001-02-08	Keygene N.V.	Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
GB9922124D0 (en)	1999-09-17	1999-11-17	Pfizer Ltd	Phosphodiesterase enzymes
US6479280B1 (en)	1999-09-24	2002-11-12	Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw	Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
US6849425B1 (en)	1999-10-14	2005-02-01	Ixsys, Inc.	Methods of optimizing antibody variable region binding affinity
DE19955408A1 (de)	1999-11-18	2001-05-23	Bayer Ag	GABA-B-Rezeptoren
WO2001040310A2 (en)	1999-11-29	2001-06-07	Unilever Plc	Immobilisation of proteins using a polypeptide segment
DK1233987T3 (da)	1999-11-29	2009-09-28	Bac Ip B V	Immobiliserede enkelt-domæne antigenbindende molekyler
UA76708C2 (uk) *	1999-12-08	2006-09-15	Сінгента Патисипейшонс Аг	Антитіло, яке застосовується в імунологічному аналізі зразка для визначення неонікотиноїдного інсектициду, білковий кон'югат для одержання антитіла, спосіб визначення концентрації неонікотиноїдного інсектициду в зразку та набір для визначення кількості неонікотиноїдного інсектициду
AU784285B2 (en)	1999-12-24	2006-03-02	Genentech Inc.	Methods and compositions for prolonging elimination half-times of bioactive compounds
US7229619B1 (en)	2000-11-28	2007-06-12	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
ATE428733T1 (de)	2000-03-14	2009-05-15	Unilever Nv	Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen
US7097840B2 (en)	2000-03-16	2006-08-29	Genentech, Inc.	Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20030190598A1 (en)	2000-05-26	2003-10-09	Jasmid Tanha	Single-domain antigen-binding antibody fragments derived from llama antibodies
US6741957B1 (en)	2000-07-21	2004-05-25	Daimlerchrysler Corporation	Analytical tire model for vehicle durability and ride comfort analysis
EP2786736A1 (fr)	2000-10-20	2014-10-08	Firmenich SA	Procédé de fabrication d'une composition parfumante sans alcool
US20040053340A1 (en)	2000-12-13	2004-03-18	De Haard Johannes Joseph	Protein arrays
US7054297B1 (en)	2000-12-28	2006-05-30	Cisco Technology, Inc.	Distribution of packets to high data rate communications devices using multicast protocols
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
WO2002076489A1 (en)	2001-03-09	2002-10-03	Dyax Corp.	Serum albumin binding moieties
DE60237282D1 (de)	2001-06-28	2010-09-23	Domantis Ltd	Doppelspezifischer ligand und dessen verwendung
US20100081792A1 (en)	2001-06-28	2010-04-01	Smithkline Beecham Corporation	Ligand
US20050271663A1 (en)	2001-06-28	2005-12-08	Domantis Limited	Compositions and methods for treating inflammatory disorders
WO2003005053A1 (de)	2001-07-04	2003-01-16	Siemens Aktiengesellschaft	Verfahren zur intensitätskorrektur eines magnetresonanzbildes
EP1425694A2 (en)	2001-08-03	2004-06-09	Medical Research Council	Method of identifying a consensus sequence for intracellular antibodies
US7371849B2 (en)	2001-09-13	2008-05-13	Institute For Antibodies Co., Ltd.	Methods of constructing camel antibody libraries
FR2829940A1 (fr)	2001-09-27	2003-03-28	Synt Em	Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central
US7084257B2 (en)	2001-10-05	2006-08-01	Amgen Inc.	Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
JP2005289809A (ja)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
AU2002351957B2 (en)	2001-11-12	2009-09-03	Merck Patent Gmbh	Modified anti-TNF alpha antibody
US7365167B2 (en)	2001-11-26	2008-04-29	Cell Matrix, Inc.	Humanized collagen antibodies and related methods
US7393648B2 (en)	2001-12-03	2008-07-01	Alexion Pharmaceuticals, Inc.	Hybrid antibodies
US20030129659A1 (en)	2001-12-03	2003-07-10	Whelihan E. Fayelle	Library screening
KR100599789B1 (ko)	2001-12-03	2006-07-12	삼성에스디아이 주식회사	방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
WO2003050531A2 (en)	2001-12-11	2003-06-19	Algonomics N.V.	Method for displaying loops from immunoglobulin domains in different contexts
AU2002360068B2 (en)	2001-12-21	2009-09-03	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Method for cloning of variable domain sequences
EP1461085A2 (en)	2002-01-03	2004-09-29	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	Immunoconjugates useful for treatment of tumours
DE10225567B4 (de)	2002-06-10	2006-07-06	Endress + Hauser Conducta Gesellschaft für Mess- und Regeltechnik mbH + Co. KG	Kommunikationsverfahren und System hierfür
JP2006512050A (ja) *	2002-06-21	2006-04-13	ダイアックス、コープ	血清タンパク質結合標的特異的リガンドとその同定方法
EP1600459A3 (en)	2002-06-28	2005-12-07	Domantis Limited	Ligand
US20060002935A1 (en)	2002-06-28	2006-01-05	Domantis Limited	Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US20080008713A1 (en)	2002-06-28	2008-01-10	Domantis Limited	Single domain antibodies against tnfr1 and methods of use therefor
EP1388571A1 (de)	2002-08-08	2004-02-11	Ciba Spezialitätenchemie Pfersee GmbH	Polyorganosiloxanzusammensetzung enthaltend quaternäre Ammoniumgruppen
US7004940B2 (en)	2002-10-10	2006-02-28	Ethicon, Inc.	Devices for performing thermal ablation having movable ultrasound transducers
EP1565482B1 (en)	2002-10-23	2014-04-30	Ludwig Institute for Cancer Research Ltd.	A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
AU2003286004A1 (en)	2002-11-08	2004-06-07	Ablynx N.V.	Single domain antibodies directed against interferon- gamma and uses therefor
ES2551682T3 (es)	2002-11-08	2015-11-23	Ablynx N.V.	Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
US20060034845A1 (en)	2002-11-08	2006-02-16	Karen Silence	Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
JP2006520584A (ja)	2002-11-08	2006-09-14	アブリンクスエン．ヴェー．	安定化単一ドメイン抗体
GB0230203D0 (en)	2002-12-27	2003-02-05	Domantis Ltd	Fc fusion
ATE444984T1 (de)	2002-12-31	2009-10-15	Nektar Therapeutics Al Corp	Hydrolysestabile maleimidendgruppen-enthaltende polymere
WO2004062551A2 (en)	2003-01-10	2004-07-29	Ablynx N.V.	RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
AU2004220325B2 (en)	2003-06-30	2011-05-12	Domantis Limited	Polypeptides
US7539903B2 (en)	2003-06-30	2009-05-26	Siemens Aktiengesellschaft	Method for monitoring the execution of a program by comparing a request with a response and introducing a falsification in a response
EP1512696A1 (en)	2003-08-14	2005-03-09	Diatos	Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
DE60334645D1 (de)	2003-11-07	2010-12-02	Ablynx Nv	Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US7432238B2 (en)	2004-04-16	2008-10-07	Stc.Unm	Human Kunitz-type inhibitor with enhanced antifibrinolytic activity
US7180370B2 (en)	2004-09-01	2007-02-20	Micron Technology, Inc.	CMOS amplifiers with frequency compensating capacitors
US7563443B2 (en)	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
GB0521621D0 (en)	2005-10-24	2005-11-30	Domantis Ltd	Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
RU2428431C2 (ru)	2004-12-02	2011-09-10	Домантис Лимитед	Слитые конструкции лекарственного средства и конъюгаты
EP3613767A1 (en)	2005-05-18	2020-02-26	Ablynx N.V.	Improved nanobodiestm against tumor cecrosis factor-alpha
DE102005023617A1 (de)	2005-05-21	2006-11-23	Aspre Ag	Verfahren zum Mischen von Farben in einem Display
US20070269422A1 (en)	2006-05-17	2007-11-22	Ablynx N.V.	Serum albumin binding proteins with long half-lives
JP2010528647A (ja)	2007-06-06	2010-08-26	ドマンティスリミテッド	ポリペプチド、抗体可変ドメインおよびアンタゴニスト
GB0724331D0 (en)	2007-12-13	2008-01-23	Domantis Ltd	Compositions for pulmonary delivery
MX2009013137A (es)	2007-06-06	2010-04-30	Domantis Ltd	Metodos para seleccionar polipeptidos resistentes a la proteasa.
AU2008328781A1 (en)	2007-11-27	2009-06-04	Ablynx N.V.	Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
AR072571A1 (es)	2008-07-18	2010-09-08	Bristol Myers Squibb Co	Composiciones monovalentes para union a cd28 y procedimientos de uso
CN106432495A (zh)	2010-07-22	2017-02-22	加利福尼亚大学董事会	抗肿瘤抗原抗体及其使用方法
IL254577B2 (en) *	2015-03-31	2023-11-01	Vhsquared Ltd	polypeptides
JP7224917B2 (ja) *	2016-03-31	2023-02-20	ソリッソファーマシューティカルズ，インク．	組成物

2006
- 2006-05-17 EP EP19184376.2A patent/EP3613767A1/en active Pending
- 2006-05-17 MX MX2016001166A patent/MX363423B/es unknown
- 2006-05-17 SI SI200631334T patent/SI1888640T1/sl unknown
- 2006-05-17 ES ES06742963T patent/ES2379283T3/es active Active
- 2006-05-17 ES ES06742962T patent/ES2384164T3/es active Active
- 2006-05-17 EP EP20110163652 patent/EP2479191A3/en not_active Withdrawn
- 2006-05-17 US US11/587,749 patent/US8188223B2/en active Active
- 2006-05-17 PL PL15172289T patent/PL2949668T3/pl unknown
- 2006-05-17 SG SG10201708038QA patent/SG10201708038QA/en unknown
- 2006-05-17 BR BR122013001996-0A patent/BR122013001996B1/pt active IP Right Grant
- 2006-05-17 JP JP2008511627A patent/JP5047950B2/ja active Active
- 2006-05-17 EP EP09173976A patent/EP2172484A3/en not_active Withdrawn
- 2006-05-17 EP EP15172289.9A patent/EP2949668B1/en active Active
- 2006-05-17 KR KR1020077026738A patent/KR101308771B1/ko active Active
- 2006-05-17 PT PT151722899T patent/PT2949668T/pt unknown
- 2006-05-17 EP EP20100175950 patent/EP2365000A3/en not_active Withdrawn
- 2006-05-17 SG SG2012064283A patent/SG184709A1/en unknown
- 2006-05-17 ES ES15172289T patent/ES2778123T3/es active Active
- 2006-05-17 EP EP06742962A patent/EP1888640B1/en active Active
- 2006-05-17 AT AT06742963T patent/ATE537188T1/de active
- 2006-05-17 BR BRPI0609224-1A patent/BRPI0609224B1/pt active IP Right Grant
- 2006-05-17 NZ NZ562695A patent/NZ562695A/en not_active IP Right Cessation
- 2006-05-17 SI SI200631287T patent/SI1888641T1/sl unknown
- 2006-05-17 DK DK06742963.9T patent/DK1888641T3/da active
- 2006-05-17 PL PL06742963T patent/PL1888641T3/pl unknown
- 2006-05-17 SI SI200632355T patent/SI2949668T1/sl unknown
- 2006-05-17 CN CN200680026278XA patent/CN101248087B/zh active Active
- 2006-05-17 DK DK06742962.1T patent/DK1888640T3/da active
- 2006-05-17 WO PCT/EP2006/004679 patent/WO2006122787A1/en not_active Ceased
- 2006-05-17 MX MX2012000384A patent/MX342271B/es unknown
- 2006-05-17 DK DK15172289T patent/DK2949668T3/da active
- 2006-05-17 PL PL06742962T patent/PL1888640T3/pl unknown
- 2006-05-17 MX MX2007014359A patent/MX2007014359A/es active IP Right Grant
- 2006-05-17 CA CA2962819A patent/CA2962819C/en active Active
- 2006-05-17 CA CA2608770A patent/CA2608770C/en active Active
- 2006-05-17 RU RU2007142444/10A patent/RU2464276C2/ru active
- 2006-05-17 AT AT06742962T patent/ATE549357T1/de active
- 2006-05-17 LT LT15172289T patent/LT2949668T/lt unknown
- 2006-05-17 EP EP06742963A patent/EP1888641B1/en active Active
- 2006-05-17 HU HUE15172289A patent/HUE045710T2/hu unknown
- 2006-05-17 WO PCT/EP2006/004678 patent/WO2006122786A2/en not_active Ceased
- 2006-05-17 PT PT06742963T patent/PT1888641E/pt unknown
- 2006-05-17 CN CN201210350044.8A patent/CN103254309B/zh active Active
- 2006-05-17 AU AU2006249144A patent/AU2006249144B2/en active Active
- 2006-05-18 TW TW095117592A patent/TWI395755B/zh active
- 2006-05-18 TW TW101148771A patent/TWI439467B/zh active
2007
- 2007-10-25 IL IL186941A patent/IL186941A/en active IP Right Grant
- 2007-11-14 NO NO20075853A patent/NO338568B1/no unknown
- 2007-11-14 CR CR9519A patent/CR9519A/es not_active Application Discontinuation
- 2007-11-14 NI NI200700291A patent/NI200700291A/es unknown
- 2007-11-15 ZA ZA200709867A patent/ZA200709867B/xx unknown
- 2007-11-19 EC EC2007007910A patent/ECSP077910A/es unknown
2009
- 2009-02-12 ZA ZA200901011A patent/ZA200901011B/xx unknown
2011
- 2011-01-14 ZA ZA2011/00385A patent/ZA201100385B/en unknown
2012
- 2012-05-02 JP JP2012105089A patent/JP5788359B2/ja active Active
- 2012-06-26 RU RU2012126722A patent/RU2634381C2/ru active
2013
- 2013-03-20 IL IL225347A patent/IL225347A/en active IP Right Grant
2014
- 2014-02-27 US US14/191,907 patent/US9067991B2/en active Active
2015
- 2015-05-07 JP JP2015094805A patent/JP6420200B2/ja active Active
- 2015-05-12 US US14/709,870 patent/US20150353635A1/en not_active Abandoned
2016
- 2016-06-17 NO NO20161028A patent/NO345340B1/no unknown
2017
- 2017-03-05 IL IL250946A patent/IL250946B/en active IP Right Grant
- 2017-03-28 JP JP2017063172A patent/JP6484660B2/ja active Active
- 2017-07-10 US US15/644,890 patent/US20170342146A1/en not_active Abandoned
2019
- 2019-05-28 US US16/423,596 patent/US11472871B2/en active Active
- 2019-11-13 CY CY20191101193T patent/CY1122672T1/el unknown
2022
- 2022-05-27 US US17/826,258 patent/US20230031229A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2006249144B2 (en)	2011-11-17
SI1888640T1 (sl)	2012-07-31
EP2365000A2 (en)	2011-09-14
US20170342146A1 (en)	2017-11-30
IL250946A0 (en)	2017-04-30
ES2384164T3 (es)	2012-07-02
MX2007014359A (es)	2008-02-06
PT1888641E (pt)	2012-03-19
BRPI0609224B1 (pt)	2021-08-17
HK1113685A1 (en)	2008-10-10
CR9519A (es)	2008-10-17
JP6484660B2 (ja)	2019-03-13
EP2479191A3 (en)	2013-03-13
US20230031229A1 (en)	2023-02-02
ECSP077910A (es)	2008-03-26
NO20161028A1 (no)	2007-11-19
NO20075853L (no)	2007-12-19
RU2007142444A (ru)	2009-06-27
TWI439467B (zh)	2014-06-01
NO345340B1 (no)	2020-12-21
JP2008539772A (ja)	2008-11-20
EP2949668A1 (en)	2015-12-02
ES2778123T3 (es)	2020-08-07
US20140335101A1 (en)	2014-11-13
TW201321410A (zh)	2013-06-01
US8188223B2 (en)	2012-05-29
JP6420200B2 (ja)	2018-11-07
EP2172484A3 (en)	2010-05-19
NI200700291A (es)	2008-05-12
ZA200709867B (en)	2008-10-29
TW200716671A (en)	2007-05-01
ES2379283T3 (es)	2012-04-24
CN101248087A (zh)	2008-08-20
BR122013001996B1 (pt)	2022-02-01
PL1888641T3 (pl)	2012-05-31
EP1888641B1 (en)	2011-12-14
JP5047950B2 (ja)	2012-10-10
EP2949668B1 (en)	2019-08-14
PL1888640T3 (pl)	2012-08-31
CN103254309A (zh)	2013-08-21
EP2172484A2 (en)	2010-04-07
RU2634381C2 (ru)	2017-10-26
RU2017133794A3 (xx)	2020-12-23
AU2006249144A1 (en)	2006-11-23
TWI395755B (zh)	2013-05-11
HUE045710T2 (hu)	2020-01-28
ZA201100385B (en)	2012-09-26
SI1888641T1 (sl)	2012-05-31
IL225347A (en)	2017-05-29
CY1122672T1 (el)	2021-03-12
EP1888641A1 (en)	2008-02-20
RU2017133794A (ru)	2019-03-28
US20090028880A1 (en)	2009-01-29
US9067991B2 (en)	2015-06-30
JP2012167112A (ja)	2012-09-06
CN101248087B (zh)	2012-09-26
IL186941A (en)	2014-05-28
EP2365000A3 (en)	2013-01-16
CA2962819A1 (en)	2006-11-23
JP5788359B2 (ja)	2015-09-30
CN103254309B (zh)	2017-09-26
ATE537188T1 (de)	2011-12-15
KR20080011395A (ko)	2008-02-04
PT2949668T (pt)	2019-10-24
WO2006122787A1 (en)	2006-11-23
CA2608770C (en)	2017-05-30
RU2012126722A (ru)	2014-01-10
NZ562695A (en)	2011-05-27
SI2949668T1 (sl)	2019-11-29
US20200079844A1 (en)	2020-03-12
PL2949668T3 (pl)	2020-03-31
KR101308771B1 (ko)	2013-09-23
SG184709A1 (en)	2012-10-30
ATE549357T1 (de)	2012-03-15
WO2006122786A3 (en)	2007-03-22
IL225347A0 (en)	2013-06-27
HK1215953A1 (en)	2016-09-30
DK1888640T3 (da)	2012-06-18
RU2464276C2 (ru)	2012-10-20
WO2006122786A2 (en)	2006-11-23
SG10201708038QA (en)	2017-10-30
JP2015157850A (ja)	2015-09-03
IL250946B (en)	2018-08-30
US11472871B2 (en)	2022-10-18
MX342271B (es)	2016-09-21
MX363423B (es)	2019-03-22
CA2962819C (en)	2021-07-27
DK1888641T3 (da)	2012-04-23
EP3613767A1 (en)	2020-02-26
EP1888640A2 (en)	2008-02-20
BRPI0609224A2 (pt)	2011-10-18
US20150353635A1 (en)	2015-12-10
DK2949668T3 (da)	2019-11-11
JP2017186318A (ja)	2017-10-12
EP1888640B1 (en)	2012-03-14
EP2479191A2 (en)	2012-07-25
IL186941A0 (en)	2008-02-09
LT2949668T (lt)	2019-11-11
NO338568B1 (no)	2016-09-05
CA2608770A1 (en)	2006-11-23

Publication	Publication Date	Title
CY1122672T1 (el)	2021-03-12	Βελτιωμενα nanobodiestm εναντι του παραγοντα νεκρωσης ογκων αλφα
MX2009012650A (es)	2010-02-18	Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
ATE541283T1 (de)	2012-01-15	Verfahren zum mischen von farben in einem display
PH12012502272A1 (en)	2017-07-26	Biological materials related to her3
WO2006122825A3 (en)	2007-10-04	Single domain vhh antibodies against von willebrand factor
MX2010005783A (es)	2010-08-10	Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
WO2008077945A3 (en)	2008-11-27	Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
WO2007042289A3 (en)	2007-10-04	Nanobodies™ and polypeptides against egfr and igf-ir
EP2470559A4 (en)	2013-07-31	COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING THEM
WO2007104529A3 (en)	2007-12-13	Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2005123916A3 (en)	2006-07-06	Glycosylation-disrupted factor vii variants
WO2005024006A8 (en)	2006-06-15	Coagulation factor VII polypeptides